a study on Merkel Cell Carcinoma
This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
I. To determine the clinical efficacy of MK-3475 (pembrolizumab) as the first systemic intervention for patients with advanced Merkel cell carcinoma (MCC).
I. To determine the clinical activity of MK-3475 as the first systemic intervention for patients with advanced MCC.
I. To determine the immune correlates of the clinical activity of MK-3475.
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 9-12 weeks for 1 year.
Recurrent Merkel Cell Carcinoma Stage IIIA Merkel Cell Carcinoma Stage IIIB Merkel Cell Carcinoma Stage IV Merkel Cell Carcinoma Pembrolizumab
Open to people ages 18 years and up
Note: patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:
© 2017 The Regents of the University of California